Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol

Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol

Background: Metastatic renal cell carcinoma (mRCC) is notably resistant to chemotherapy and radiotherapy. However, tyrosine kinase inhibitors (TKIs) and checkpoint immunotherapy have significantly improved outcomes. Still, about 20% of patients experience disease progression as their best response t...

Full description

Saved in:
Bibliographic Details
Main Authors: Jakob N. Henriksen, Charlotte U. Andersen, Frede Donskov, Elke Hoffmann-Lücke, Eva Greibe, Niels Fristrup
Format: Article
Language:English
Published: Medical Journals Sweden 2025-06-01
Series:Acta Oncologica
Subjects:
Metastatic renal cell carcinoma
tyrosine kinase inhibitors
therapeutic drug monitoring
personalized medicine
toxicity management
Online Access:https://medicaljournalssweden.se/actaoncologica/article/view/43693
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items